DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care
Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges
More frequent engagement on the Dario platform associated with fewer inpatient and ER events
NEW YORK, Nov. 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of a new peer-reviewed study in the Journal of Medical Internet Research (JMIR), a highly influential digital health journal, evaluating healthcare utilization and medical costs among Dario users compared to matched non-users receiving usual care. The study, "Effects of a Digital Health Intervention for Adults with Type 2 Diabetes Mellitus on Health Care Resource Use and Health Care Charges in the United States: Retrospective Cohort Study," was not authored by Dario, but rather conducted by researchers at Sanofi and Symphony Health.
The direct medical cost of diabetes in the U.S. was estimated at over $300 billion in 2022, with more than 38 million Americans living with diabetes, representing an estimated $31 billion serviceable addressable market for Dario.
This rigorous, third-party analysis directly addresses one of the most important questions that payers and employers have for their solution partners, namely: Do digital interventions reduce real-world healthcare burden and cost compared to people already receiving usual care? The study's authors found that Dario users had consistently lower utilization rates and charges than matched individuals receiving usual care.
The study examined 12-month outcomes for 2,445 adults with type 2 diabetes using Dario's platform compared to 7,334 matched individuals receiving usual care. Unlike many digital health evaluations that rely on pre/post comparisons, this study used a high-stringency matched-cohort design drawing from a large real-world claims database – representing one of the most rigorous economic evaluations of a digital health solution to date. Additionally, most digital health studies compare effects between treated and non-treated groups, which tends to inflate the impact of an intervention. The higher bar of comparing an intervention group to a group receiving usual care is far less common.
Across multiple measures of healthcare utilization, charges and estimated costs, Dario users demonstrated consistently lower burden compared to a matched group receiving usual care:
- 23.5% lower inpatient hospitalization rates
- 9.3% lower all-cause healthcare resource utilization (HCRU)
(inpatient hospitalizations + emergency room visits) - 26% lower all-cause HCRU charges
- Estimated gross cost savings of $5,077 per patient per year (PPPY) based on standard cost-to-charge conversion methodologies
- Shorter inpatient lengths of stay
- Lower 30-day readmission rates
- A strong dose-response relationship, with more frequent engagement on the Dario platform associated with fewer inpatient and ER events
Collectively, these findings reinforce that a holistic digital platform integrating connected devices, behavior-change science and real-time engagement can meaningfully reduce avoidable utilization – delivering benefits beyond what is typically achieved in usual care alone.
The results add to the growing body of evidence supporting Dario's approach and its ability to help employers, payers and health systems improve chronic condition management while reducing the cost of care.
"Real-world economic validation from peer-reviewed research is critical for organizations evaluating digital health solutions," said Yifat Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs at Dario. "This study shows that when members engage with Dario's connected devices, personalized guidance and behavioral support, the impact on reducing costly hospital and ER events can be both meaningful and sustained."
"This study shows what matters most to health plans and employers: when enterprises use a well-designed digital intervention, they can reduce avoidable hospitalizations and lower the cost of care, even for populations already receiving care," added Omar Manejwala, MD, Chief Medical Officer at Dario. "This study provides some of the strongest evidence to date that employers and health plans can have confidence in Dario's financial impact."
The full article is available open access on the JMIR website: https://www.jmir.org/2025/1/e67320/
About DarioHealth Corp. (NASDAQ:DRIO)
DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the Company's potential addressable market, the benefits to be realized by the Company's integrated digital solution for employers and members, that the analysis is a critical milestone for the Company, that the Company's digital care can deliver meaningful and sustainable results that matter to both patients and payers, the belief that the study shows that when members engage with Dario's connected devices, personalized guidance and behavioral support, the impact on reducing costly hospital and ER events can be both meaningful and sustained, the belief that the study provides some of the strongest evidence to date that employers and health plans can have confidence in Dario's financial impact. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
[email protected]
+1-201-785-6310
Rob Halpern
SVP Marketing
[email protected]
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:SOURCE DarioHealth Corp.